<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215224</url>
  </required_header>
  <id_info>
    <org_study_id>GliomaAI-4</org_study_id>
    <nct_id>NCT04215224</nct_id>
  </id_info>
  <brief_title>Histopathology Images Based Survival Prediction of Glioma Patients Using Artificial Intelligence</brief_title>
  <official_title>Histopathology Images Based Survival Prediction of Patients With Primary Glioma Using Deep Learning or Machine Learning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Zhengzhou University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry aims to collect clinical, molecular and histopathology imaging including
      detailed survival data, clinical parameters, molecular pathology (1p/19q codeletion, MGMT
      methylation, IDH and TERTp mutations, etc) and images of HE slices in primary gliomas. By
      leveraging artificial intelligence, this registry will seek to construct and refine
      hstopathology imaging based algorithms that able to predict patients' survivals in the frame
      of molecular pathology or subgroups of gliomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-invasive and precise prediction for survivals of glioma patients is challenging. With the
      development of artificial intelligence, much more potential lies in the histopathology images
      of HE slices in primary gliomas could be excavated to aid prediction of patients' prognosis
      in the frame of molecular pathology of gliomas. The creation of a registry for primary glioma
      with detailed survival data, molecular pathology, histopathology image data and with
      sufficient sample size for deep learning (&gt;1000) provides opportunities for personalized
      prediction of survival of glioma patients with non-invasiveness and precision.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>120 Months</target_duration>
  <primary_outcome>
    <measure>AUC of survival prediction performance</measure>
    <time_frame>up to 10 years</time_frame>
    <description>AUC of survival prediction performance=sensitivity+specificity-1</description>
  </primary_outcome>
  <enrollment type="Anticipated">3500</enrollment>
  <condition>Glioma</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Histopathology images based survival prediction for glioma patients</intervention_name>
    <description>Histopathology images based survival prediction of glioma patients in the frame of molecular pathology by leveraging AI</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All participants have signed the informed consent. Fresh frozen tissues of participants are
      collected immediately after tumor resection and preserved in liquid nitrogen. Whole exome
      sequencing, RNA sequencing and proteomics are planed to be conducted.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Paitents with newly diagnosed glioma who receive tumor resection with life expectancy of
        greater than 3 months
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have radiologically and histologically confirmed diagnosis of primary
             glioma

          -  Life expectancy of greater than 3 months

          -  Must receive tumor resection

          -  Signed informed consent

        Exclusion Criteria:

          -  No gliomas

          -  No sufficient amount of tumor tissues for detection of molecular pathology

          -  Patients who are pregnant or breast feeding

          -  Patients who are suffered from severe systematic malfuctions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhenyu Zhang, Dr.</last_name>
    <phone>+86 17839973727</phone>
    <email>fcczhangzy1@zzu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenyu Zhang, Dr.</last_name>
      <phone>+86 17839973727</phone>
      <email>fcczhangzy1@zzu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>December 31, 2019</last_update_submitted>
  <last_update_submitted_qc>December 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Zhenyu Zhang</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Prognosis</keyword>
  <keyword>Histopathology imaging</keyword>
  <keyword>Deep Learning</keyword>
  <keyword>Machine Learning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

